Tag: pharmaceuticals

  • Biopharm Company Consolidates, Cuts 25% of Workforce

    Halozyme Therapeutics Inc., a biopharmaceutical company in San Diego, California said on Monday it would reduce its new research and development work to concentrate on existing drug products and commitments to pharmaceutical manufacturers. This consolidation will result in the company cutting its workforce by 25 percent. The company’s announcement noted Halozyme Therapeutics will focus its…

  • Patent Issued for Dupuytren’s Contracture Drug

    Auxilium Pharmaceuticals Inc. in Malvern, Pennsylvania, a developer of specialty biopharmaceuticals, said today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 7,811,560 covering purified collagenase, the active component in Auxilium’s drug Xiaflex. The drug is a treatment for Dupuytren’s contracture a thickening of the palm’s deep connective tissue. The patent, says…

  • Clinical Trial of Stem Cell Therapy Underway

    Geron Corporation in Menlo Park, California said today the first patient has enrolled in the clinical trial of its drug GRNOPC1, that contains oligodendrocyte progenitor cells derived from human embryonic stem cells (hESC). The objective of this Phase 1 study is to assess the safety and tolerability of GRNOPC1 in patients with complete American Spinal…

  • ImmunoGen, Novartis to Collaborate on Cancer Drugs

    ImmunoGen Inc., a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis, a pharmaceutical manufacturer headquartered in Basel, Switzerland. Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for…

  • Biotech, Pharma Companies Partner on Schizophrenia Research

    Takeda Pharmaceutical Company, a global drug manufacturer in Osaka, Japan, and Envoy Therapeutics Inc., a drug discovery company in Jupiter, Florida, said today they formed a three-year research alliance aimed at discovering drugs for schizophrenia with greater efficacy and safety compared to current therapies. Envoy’s technology, called bacTRAP, combines genetic engineering with molecular biology techniques…

  • Novartis to Develop Flu Vaccines with Synthetic Genomics

    Novartis, a global pharmaceutical company based in Basel, Switzerland, says today it will join with Synthetic Genomics Vaccines Inc. (SGVI), in La Jolla, California to apply a combination of synthetic biology and genomics to accelerate production of influenza seed strains required for vaccine manufacturing. Seed strains are starter cultures of a virus, and the base…

  • Anxiety/Depression Drug Trials Approved in France

    Bionomics Limited, a drug development company in Adelaide, Australia, says the French national medical agency and ethics committee for Strasburg Hospital have approved the company’s request to conduct clinical trials for BNC210, Bionomics’ treatment of anxiety and depression now in development. The first clinical study will examine whether BNC210 reduces panic and anxiety symptoms induced…

  • NIH Awards $1.8 Million in Small Business Grants for Vaccines

    Altravax Inc. in Fargo, North Dakota received two grants from National Institutes of Health (NIH) for research on vaccines for HIV-1. A third NIH grant supports the company’s work on vaccines for an influenza virus. All three grants, valued at $1.8 million, are awarded under NIH’s Small Business Innovation Research (SBIR) program. Two of the…

  • FDA Okays Myelodysplastic Syndromes Trial Protocol

    Onconova Therapeutics Inc., a biotech company in Newtown, Pennsylvania, says it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of a Phase 3 clinical trial for the company’s drug Estybon. The drug is a monotherapy for patients with myelodysplastic syndromes (MDS), diseases affecting…

  • FDA Fast-Tracks Antibody for Inhalational Anthrax Treatment

    Emergent BioSolutions Inc. in Rockville, Maryland says that its program for developing AVP-21D9, an antibody for the treatment of inhalational anthrax, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Anthrax commonly affects hoofed animals such as sheep and goats, but also humans who come into contact with the infected…